Home › Funds › ACORN CAPITAL ADVISORS, LLC › JBIO
ACORN CAPITAL ADVISORS, LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
ACORN CAPITAL ADVISORS, LLC reported holding 986,760 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$21.9M, representing 5.98% of its reported portfolio and ranking #6 among its reported holdings. ACORN CAPITAL ADVISORS, LLC has disclosed JBIO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACORN CAPITAL ADVISORS, LLC's JBIO position evolved
ACORN CAPITAL ADVISORS, LLC first disclosed a stake in JBIO in Q1 2026 at 786,760 shares (US$11.1M). The position peaked in Q2 2026 at 986,760 shares, worth US$21.9M. Across 2 filings, ACORN CAPITAL ADVISORS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 986,760 shares valued at US$21.9M — an increase of 200,000 shares quarter over quarter.. Notable position changes include a 25% increase in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 786.76K | $11.05M | New |
| Q2 2026 | 986.76K | $21.93M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.67M sh · $81.57M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Paradigm Biocapital Advisors LP 2.86M sh · $63.49M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Remedium Capital Partners, LLC 1.58M sh · $35.06M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Logos Global Management LP 1.12M sh · $25.00M · Q2 2026
- Versant Venture Management, LLC 991.78K sh · $22.04M · Q2 2026
- Foresite Capital Management VI LLC 886.67K sh · $19.70M · Q2 2026
More on ACORN CAPITAL ADVISORS, LLC
FAQ
How long has ACORN CAPITAL ADVISORS, LLC held JBIO?
ACORN CAPITAL ADVISORS, LLC has disclosed JBIO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ACORN CAPITAL ADVISORS, LLC's current position in JBIO?
As of Q2 2026, ACORN CAPITAL ADVISORS, LLC holds 986.76K shares of JBIO (JADE BIOSCIENCES INC), valued at $21.93M, representing 5.98% of its reported portfolio and ranking #6.
Has ACORN CAPITAL ADVISORS, LLC been buying or selling JBIO?
In the latest 13F filing (Q2 2026), ACORN CAPITAL ADVISORS, LLC increased its position in JBIO. The position peaked in Q2 2026 at 986.76K shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.